TY - JOUR
T1 - Immunoreactive endothelin in the human kidney
T2 - Comparison with natriuretic peptides
AU - Takahashi, Kazuhiro
AU - Sone, Masahiko
AU - Totsune, Kazuhito
AU - Satoh, Fumitoshi
AU - Murakami, Osamu
AU - Ohneda, Makoto
AU - Mouri, Toraichi
PY - 1995
Y1 - 1995
N2 - The presence of immunoreactive endothelin (IR-ET) was studied by radioimmunoassay in human kidney with and without clinical renal failure, and the levels were compared with those of three natriuretic peptides: Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). Kidney tissues were obtained at autopsy from three subjects with renal disorders (diabetic nephropathy, renal tubular necrosis, and end-stage kidney disease). Normal renal tissue was obtained at surgery from two patients with renal cell carcinoma. IR-ET was detected in three diseased kidneys obtained at autopsy (0.101 ± 0.043 pmol/g wet weight, mean ± SD) but not in tissues of two normal kidneys obtained at surgery (<0.015 pmol/g wet weight). Reverse-phase HPLC showed that most of the IR-ET in the kidney (>90%) was eluted in the position of ET-1. IR-ANP(0.23 ± 0.06 pmol/g wet weight), IR-BNP (1.15 ± 0.94 pmol/g wet weight), and IR-CNP (0.44 ± 0.16 pmol/g wet weight) were detected in all samples examined. Higher concentrations of IR-BNP were found in three diseased kidneys obtained at autopsy (1.70 ± 0.83 pmol/g wet weight vs. mean in two normal kidney tissues, 0.32 pmol/g wet weight). Such increases were not observed in IR-ANP or IR-CNP. These findings indicate that IR-ET is present in the human diseased kidney even in end-stage disease, with high concentrations comparable to those ol natriuretic peptides. This raises the possibility that the production of ET-1 and BNP is increased in kidneys of patients with renal disorders.
AB - The presence of immunoreactive endothelin (IR-ET) was studied by radioimmunoassay in human kidney with and without clinical renal failure, and the levels were compared with those of three natriuretic peptides: Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). Kidney tissues were obtained at autopsy from three subjects with renal disorders (diabetic nephropathy, renal tubular necrosis, and end-stage kidney disease). Normal renal tissue was obtained at surgery from two patients with renal cell carcinoma. IR-ET was detected in three diseased kidneys obtained at autopsy (0.101 ± 0.043 pmol/g wet weight, mean ± SD) but not in tissues of two normal kidneys obtained at surgery (<0.015 pmol/g wet weight). Reverse-phase HPLC showed that most of the IR-ET in the kidney (>90%) was eluted in the position of ET-1. IR-ANP(0.23 ± 0.06 pmol/g wet weight), IR-BNP (1.15 ± 0.94 pmol/g wet weight), and IR-CNP (0.44 ± 0.16 pmol/g wet weight) were detected in all samples examined. Higher concentrations of IR-BNP were found in three diseased kidneys obtained at autopsy (1.70 ± 0.83 pmol/g wet weight vs. mean in two normal kidney tissues, 0.32 pmol/g wet weight). Such increases were not observed in IR-ANP or IR-CNP. These findings indicate that IR-ET is present in the human diseased kidney even in end-stage disease, with high concentrations comparable to those ol natriuretic peptides. This raises the possibility that the production of ET-1 and BNP is increased in kidneys of patients with renal disorders.
KW - Endothelin
KW - Kidney-Renal failure
KW - Natriuretic peptide
KW - Radioimmunoassay
UR - http://www.scopus.com/inward/record.url?scp=0028851572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028851572&partnerID=8YFLogxK
U2 - 10.1097/00005344-199506263-00150
DO - 10.1097/00005344-199506263-00150
M3 - Article
C2 - 8587463
AN - SCOPUS:0028851572
SN - 0160-2446
VL - 26
SP - S510-S512
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
ER -